Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 1, 2019, Pages

  Kayssi, Ahmed ^a   Al Jundi, Wissam ^a   Papia, Giuseppe ^a   Kucey, Daryl S ^a   Forbes, Thomas ^a   Rajan, Dheeraj K ^a   Neville, Richard ^b   Dueck, Andrew D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANKLE BRACHIAL INDEX; ECHOGRAPHY; FEMORAL ARTERY; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; LEG AMPUTATION; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPLITEAL ARTERY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TARGET LESION REVASCULARIZATION; TREATMENT OUTCOME; VASCULAR PATENCY; WALKING; AMPUTATION; META ANALYSIS; PROCEDURES; RECURRENT DISEASE; STENOSIS, OCCLUSION AND OBSTRUCTION; STENT;

AMPUTATION; ANGIOPLASTY, BALLOON; ANKLE BRACHIAL INDEX; CONSTRICTION, PATHOLOGIC; FEMORAL ARTERY; HUMANS; POPLITEAL ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STENTS; VASCULAR PATENCY;

EID: 85060542233     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012510.pub2     Document Type: Review

References (45)

1. Krankenberg H. FAIR drug eluting balloon vs. PTA for superficial femoral artery in-stent restenosis 12-month results. The Leipzig Interventional Course. Leipzig 28-31 January 2014. 9830565
2. Krankenberg H, Tübler T, Ingwersen M, Schlüter M, Scheinert D, Blessing E, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized femoral artery in-stent restenosis (FAIR) trial. Circulation 2015;132(23):2230-6. 9830564
3. NCT01305070. Standard balloon angioplasty versus angioplasty with a paclitaxel-eluting balloon for Femoral Artery In-stent Restenosis (FAIR). clinicaltrials.gov/ct2/show/NCT01305070 (date first received February 28, 2011). 9830566
4. NCT01083394. Paclitaxel eluting balloon and conventional balloon for in-stent restenosis of the superficial femoral artery (ISAR-PEBIS). clinicaltrials.gov/ct2/show/NCT01083394 (date first received March 9, 2010). 9830568
5. Ott I, Cassese S, Groha P, Steppich B, Voll F, Hadamitzky M, et al. ISAR-PEBIS (paclitaxel-eluting balloon versus conventional balloon angioplasty for in-stent restenosis of superficial femoral artery): a randomized trial. Journal of the American Heart Association 2017;6(7):pii: e006321. 9830569
6. Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC Cardiovascular Interventions 2016;9(13):1386-92. 9830571
7. Kinstner CM, Schoder M, Funovics MA, Willfort-Ehringer A, Gschwandtner M, Ristl R, et al. A monocenter randomized clinical trial of PAClitaxel drUgeluting Balloon versus standard percutaneous transluminal Angioplasty to reduce restenosis in patients with in-stent stenoses in the superficial femoral and proximal popliteal artery (PACUBA I Trial). Cardiovascular and Interventional Radiology 2015;38(3 Suppl 1):S288. 9830572
8. NCT01247402. Paclitaxel balloon versus standard balloon in in-stent restenoses of the superficial femoral artery (PACUBA I Trial) (PACUBA 1). clinicaltrials.gov/ct2/show/NCT01247402 (date first received November 24, 2010). 9830573
9. Bosiers M, Deloose K, Callaert J, Verbist J, Hendriks J, Lauwers P, et al. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial. Journal of Endovascular Therapy 2015;22(1):1-10. 9830575
10. Albrecht T, Meyer D, Müller-Hülsbeck S, Ott I, Redlich U, Ricke J, et al. Preliminary angiographic and clinical 6-month results of the CONSEQUENT trial. The Leipig Interventional Course. Leipzig 26-29 January 2016. 9830577
11. NCT01970579. Clinical trial on peripheral arteries treated with SeQuent® Please P Paclitaxel coated balloon catheter (ConSeQuent). clinicaltrials.gov/ct2/show/NCT01970579 (date first received October 28, 2013). 9830578
12. Liistro F, Angioli P, Porto I, Ricci L, Ducci K, Grotti S, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. Journal of Endovascular Therapy 2014;21(1):1-8. 9830580
13. Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC.Cardiovascular interventions 2015;8:92-101. 9830582
14. Dippel EJ, Makam P, Kovach RC, George JC, et al. EXCITE ISR: a prospective, randomized controlled trial of Excimer laser atherectomy vs balloon angioplasty for the treatment of femoropopliteal in-stent restenosis. Journal of the American College of Cardiology 2014; Vol. 64, issue Suppl 11. 9830583
15. NCT01330628. Randomized study of laser and balloon angioplasty versus balloon angioplasty to treat peripheral in-stent restenosis (EXCITE ISR). clinicaltrials.gov/ct2/show/NCT01330628 (date first received April 7, 2011). 9830584
16. NCT00481780. Conventional balloon angioplasty vs. cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis - a randomized controlled pilot trial. clinicaltrials.gov/ct2/show/NCT00481780 (date first received June 4, 2007). 9830586
17. NCT02832024. Clinical study of stent versus direct atherectomy versus angioplasty to treat lower limb in-stent restenosis. clinicaltrials.gov/ct2/show/NCT02832024 (date first received July 13, 2016). 9830588
18. Deloose K. RELINE randomized clinical trial: Viabahn covered stents vs PTA. The Leipzig Interventional Course. Leipzig 28-31 January 2014. 9830590
19. NCT01108861. GORE VIABAHN® versus plain old balloon angioplasty (POBA) for superficial femoral artery (SFA) in-stent restenosis (RELINE). clinicaltrials.gov/ct2/show/NCT01108861 (date first received April 22, 2010). 9830591
20. NCT01594684. Cotavance™ paclitaxel-coated balloon versus uncoated balloon angioplasty for treatment of in-stent restenosis in SFA and popliteal arteries. clinicaltrials.gov/ct2/show/results/NCT01594684 (date first received May 9, 2012). 9830593
21. ChiCTR-TRC-14004848. Drug-eluting balloon versus standard balloon angioplasty for the treatment of in-stent restenosis in the femoral-popliteal artery: a randomized, controlled prospective study. chictr.org.cn/hvshowproject.aspx?id=11037 (date first received May 1, 2015). 9830595
22. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. Journal of the American College of Cardiology 2014;63(24):2659-73.
23. Ali FN, Carman TL. Medical management for chronic atherosclerotic peripheral arterial disease. Drugs 2012;72(16):2073-85.
24. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
25. Canaud L, Ozdemir BA, Belli AM, Loftus IM, Thompson MM, Hinchliffe RJ. Infrainguinal angioplasty with drug-eluting stents and balloons. Journal of Vascular Surgery 2014;59(6):1721-36.
26. Cassese S, Ndrepepa G, Kufner S, Byrne RA, Giacoppo D, Ott I, et al. Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries: a meta-analysis. EuroIntervention 2017;13(4):483-9.
27. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. Journal of Vascular Surgery 2015;61(3 Suppl):2S-41S.
28. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circulation Research 2015;116(9):1509-26.
29. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
31. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
32. Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart 2013;99(5):327-33.
33. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opinion on Drug Safety 2007;6(5):609-21.
34. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. Journal of the American Medical Association 2001;286(13):1599-606.
35. Mills JL, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on Wound, Ischemia, and foot Infection (WIfI). Journal of Vascular Surgery 2014;59(1):220-34.
36. Ontario Health Technology Advisory Committee. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis. Ontario Health Technology Assessment Series 2010;10(18):1-88.
37. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
38. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
39. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
40. Singh GD, Armstrong EJ, Laird JR. Femoropopliteal in-stent restenosis: current treatment strategies. Journal of Cardiovascular Surgery 2014;55(3):325-33.
41. Stary H, Chandler AB, Glagov S, Guyton JR, Insull W, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89(5):2462-78.
42. Sterne JAC, Egger M, Moher D, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
43. Waksman R, Pakala R. Drug-eluting balloon: the comeback kid?. Circulation Cardiovascular Interventions 2009;2(4):352-8.
44. Wu R, Li Z, Wang M, Chang G, Yao C, Wang S. Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis. International Journal of Surgery 2017;42:72-82.
45. Kayssi A, Al-Jundi W, Papia G, Kucey DS, Forbes T, Rajan DK, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012510]